Burger’s Medicinal Chemistry, Drug Discovery and Development
Explore the freshly updated flagship reference for medicinal chemists and pharmaceutical professionals
The newly revised eighth edition of the eight-volume Burger’s Medicinal Chemistry, Drug Discovery and Development is the latest installment in this celebrated series covering the entirety of the drug development and discovery process. With the addition of expert editors in each subject area, this eight-volume set adds 35 chapters to the extensive existing chapters. New additions include analyses of opioid addiction treatments, antibody and gene therapy for cancer, blood-brain barrier, HIV treatments, and industrial-academic collaboration structures.
Along with the incorporation of practical material on drug hunting, the set features sections on drug discovery, drug development, cardiovascular diseases, metabolic diseases, immunology, cancer, anti-Infectives, and CNS disorders. The text continues the legacy of previous volumes in the series by providing recognized, renowned, authoritative, and comprehensive information in the area of drug discovery and development while adding cutting-edge new material on issues like the use of artificial intelligence in medicinal chemistry.
Included:*Volume 1: Methods in Drug Discovery, edited by Kent D. Stewart*Volume 2: Discovering Lead Molecules, edited by Kent D. Stewart*Volume 3: Drug Development, edited by Ramnarayan S. Randad and Michael Myers*Volume 4: Cardiovascular, Endocrine, and Metabolic Diseases, edited by Scott D. Edmondson*Volume 5: Pulmonary, Bone, Immunology, Vitamins, and Autocoid Therapeutic Agents, edited by Bryan H. Norman*Volume 6: Cancer, edited by Barry Gold and Donna M. Huryn*Volume 7: Anti-Infectives, edited by Roland E. Dolle*Volume 8: CNS Disorders, edited by Richard A. Glennon
Perfect for research departments in the pharmaceutical and biotechnology industries, Burger’s Medicinal Chemistry, Drug Discovery and Development can be used by graduate students seeking a one-stop reference for drug development and discovery and deserves its place in the libraries of biomedical research institutes, medical, pharmaceutical, and veterinary schools.
Donald J. Abraham is Emeritus Professor of Medicinal Chemistry and Emeritus Director of the Institute for Structural Biology and Drug Discovery at Virginia Commonwealth University. He is a member of the Hall of Fame of the American Chemical Society's Medicinal Chemistry Division.
Michael Myers, PhD is Senior Director of Due Diligence at Lilly Research Labs. He has worked in drug discovery and development for over 30 years. He holds over 35 patents and has led efforts in evaluating new lead generation technologies and processes in early drug discovery, predictive ADMET, and computational chemistry.
Kent D. Stewart, PhD (Volume Editor) is Associate Professor of Basic Pharmaceutical Sciences at High Point University. Previously, he worked for over 25 years in the industry at Burroughs Wellcome, AbbVie, and Abbott Laboratories.
